<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:hpo ids='HP_0100580'>Barrett's esophagus</z:hpo> is a condition in which the <z:mpath ids='MPATH_458'>normal</z:mpath> stratified squamous epithelium is replaced by metaplastic columnar epithelium that predisposes to the development of esophageal <z:mp ids='MP_0009308'>adenocarcinoma</z:mp> </plain></SENT>
<SENT sid="1" pm="."><plain><z:e sem="disease" ids="C0178874" disease_type="Neoplastic Process" abbrv="">Neoplastic progression</z:e> in <z:hpo ids='HP_0100580'>Barrett's esophagus</z:hpo> occurs by a multistep process associated with genomic instability and the development of aneuploid cell populations </plain></SENT>
<SENT sid="2" pm="."><plain>p53 protein overexpression and allelic deletions on chromosome 17p have been shown to be present in some Barrett's <z:mp ids='MP_0009308'>adenocarcinomas</z:mp>, but the stage in <z:e sem="disease" ids="C0178874" disease_type="Neoplastic Process" abbrv="">neoplastic progression</z:e> at which p53 protein overexpression develops has not been investigated </plain></SENT>
<SENT sid="3" pm="."><plain>To determine the stages in <z:e sem="disease" ids="C0178874" disease_type="Neoplastic Process" abbrv="">neoplastic progression</z:e> at which p53 protein overexpression could be detected, biopsy specimens from patients with <z:hpo ids='HP_0100580'>Barrett's esophagus</z:hpo> at <z:hpo ids='HP_0000001'>all</z:hpo> stages of histological progression from Barrett's <z:mpath ids='MPATH_160'>metaplasia</z:mpath> negative for <z:mpath ids='MPATH_589'>dysplasia</z:mpath> to esophageal <z:mp ids='MP_0009308'>adenocarcinoma</z:mp> were investigated using a multiparameter flow-cytometric assay </plain></SENT>
<SENT sid="4" pm="."><plain>p53 protein overexpression was found in 1 of 21 patients (5%) with Barrett's <z:mpath ids='MPATH_160'>metaplasia</z:mpath> negative for <z:mpath ids='MPATH_589'>dysplasia</z:mpath>, 2 of 13 patients (15%) with Barrett's <z:mpath ids='MPATH_160'>metaplasia</z:mpath> with abnormalities in the indefinite/low-grade <z:mpath ids='MPATH_589'>dysplasia</z:mpath> range, 5 of 11 patients (45%) with high-grade <z:mpath ids='MPATH_589'>dysplasia</z:mpath>, and 8 of 15 patients (53%) with Barrett's <z:mp ids='MP_0009308'>adenocarcinoma</z:mp> (P less than 0.01) </plain></SENT>
<SENT sid="5" pm="."><plain>p53 protein overexpression was found in 9% of patients with <z:hpo ids='HP_0100580'>Barrett's esophagus</z:hpo> who had neither high-grade <z:mpath ids='MPATH_589'>dysplasia</z:mpath> nor <z:mp ids='MP_0009308'>adenocarcinoma</z:mp> </plain></SENT>
<SENT sid="6" pm="."><plain>Whether or not patients whose biopsy specimens show p53 protein overexpression are at increased risk for progression to <z:mp ids='MP_0009308'>adenocarcinoma</z:mp> can be determined by prospective endoscopic surveillance </plain></SENT>
</text></document>